EP3534912A4 - Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer - Google Patents

Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer Download PDF

Info

Publication number
EP3534912A4
EP3534912A4 EP17867742.3A EP17867742A EP3534912A4 EP 3534912 A4 EP3534912 A4 EP 3534912A4 EP 17867742 A EP17867742 A EP 17867742A EP 3534912 A4 EP3534912 A4 EP 3534912A4
Authority
EP
European Patent Office
Prior art keywords
halouracil
cancer
treatment
modified micrornas
micrornas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17867742.3A
Other languages
German (de)
English (en)
Other versions
EP3534912A1 (fr
Inventor
Jingfang Ju
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of EP3534912A1 publication Critical patent/EP3534912A1/fr
Publication of EP3534912A4 publication Critical patent/EP3534912A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17867742.3A 2016-11-01 2017-10-30 Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer Pending EP3534912A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662415740P 2016-11-01 2016-11-01
US201662422298P 2016-11-15 2016-11-15
US201762464491P 2017-02-28 2017-02-28
PCT/US2017/059011 WO2018085198A1 (fr) 2016-11-01 2017-10-30 Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer

Publications (2)

Publication Number Publication Date
EP3534912A1 EP3534912A1 (fr) 2019-09-11
EP3534912A4 true EP3534912A4 (fr) 2020-10-07

Family

ID=62077036

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17867742.3A Pending EP3534912A4 (fr) 2016-11-01 2017-10-30 Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer

Country Status (10)

Country Link
EP (1) EP3534912A4 (fr)
JP (2) JP7130639B2 (fr)
KR (2) KR102502248B1 (fr)
CN (1) CN110290794A (fr)
AU (1) AU2017353907B2 (fr)
BR (1) BR112019008810A2 (fr)
CA (1) CA3042401A1 (fr)
MX (2) MX2019005101A (fr)
SG (1) SG11202104571RA (fr)
WO (1) WO2018085198A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110527728A (zh) * 2013-08-08 2019-12-03 纽约州州立大学研究基金会 作为子宫颈癌和存活期的生物标记物的角蛋白
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US11584932B2 (en) * 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
EP3937980A4 (fr) * 2019-03-14 2023-08-02 The Research Foundation for The State University of New York Miarn modifiés et leur utilisation dans le traitement du cancer
CA3156667A1 (fr) * 2019-10-02 2021-04-08 Sirnaomics, Inc. Oligonucleotides comprenant des analogues de nucleosides
CN115515686A (zh) * 2020-03-18 2022-12-23 纽约州州立大学研究基金会 修饰的短干扰rna组合物及其在癌症治疗中的用途
WO2021262919A2 (fr) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer
IL326708A (en) * 2023-08-22 2026-04-01 Univ New York State Res Found 5-Hydrouracil-modified double-stranded nucleic acids and their use in cancer treatment
WO2025196322A2 (fr) * 2024-03-22 2025-09-25 BioNTech SE Polynucléotides cytotoxiques, particules contenant les polynucléotides cytotoxiques et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096573A1 (fr) * 2011-01-11 2012-07-19 Interna Technologies B.V. Miarn dans le traitement de maladies et d'états pathologiques associés à la néo-angiogenèse
WO2013056216A1 (fr) * 2011-10-14 2013-04-18 New York University Microarns et leurs procédés d'utilisation
WO2014100252A1 (fr) * 2012-12-18 2014-06-26 University Of Washington Through Its Center For Commercialization Procédés et compositions permettant de moduler la maturation de l'arn

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
CA2845251A1 (fr) * 2005-09-12 2007-03-22 The Ohio State University Research Foundation Compositions et leurs procedes de preparation
EP2094848A2 (fr) * 2006-09-19 2009-09-02 Asuragen, INC. GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE
EP2300017A4 (fr) * 2008-06-05 2012-12-12 Univ New York State Res Found Arnmi en tant que cibles thérapeutiques dans le cancer
WO2010108192A1 (fr) * 2009-03-20 2010-09-23 The Research Foundation Of State University Of New York Miarn comme cibles thérapeutiques en cas de cancer
KR100998365B1 (ko) * 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
US9333218B2 (en) * 2010-07-15 2016-05-10 Emory University MicroRNA compositions and methods related thereto
US9096853B2 (en) * 2012-09-24 2015-08-04 U.S. Department Of Veterans Affairs Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
WO2014186462A1 (fr) * 2013-05-15 2014-11-20 The Research Foundation For The State University Of New York Microarn-129 comme biomarqueur du cancer colorectal

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012096573A1 (fr) * 2011-01-11 2012-07-19 Interna Technologies B.V. Miarn dans le traitement de maladies et d'états pathologiques associés à la néo-angiogenèse
WO2013056216A1 (fr) * 2011-10-14 2013-04-18 New York University Microarns et leurs procédés d'utilisation
WO2014100252A1 (fr) * 2012-12-18 2014-06-26 University Of Washington Through Its Center For Commercialization Procédés et compositions permettant de moduler la maturation de l'arn

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FESLER ET AL.: "Abstract 4403: Development of 5-FU modified tumor suppressor miRNAs as a platform for miRNA based cancer therapeutics | Cancer Research", 1 July 2018 (2018-07-01), XP055685588, Retrieved from the Internet <URL:https://cancerres.aacrjournals.org/content/78/13_Supplement/4403> [retrieved on 20200415] *
JENNY K W LAM ET AL: "siRNA Versus miRNA as Therapeutics for Gene Silencing", MOLECULAR THERAPY-NUCLEIC ACIDS, vol. 4, 1 January 2015 (2015-01-01), US, pages 1 - 20, XP055380675, ISSN: 2162-2531, DOI: 10.1038/mtna.2015.23 *
S.-Y. WU ET AL: "Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity", NUCLEIC ACIDS RESEARCH, vol. 41, no. 8, 1 April 2013 (2013-04-01), pages 4650 - 4659, XP055685599, ISSN: 0305-1048, DOI: 10.1093/nar/gkt120 *
See also references of WO2018085198A1 *
VA-LIN CHIU AND TARIQ M RANA: "siRNA function in RNAi: A chemical modification analysis", RNA, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 9, no. 9, 1 January 2003 (2003-01-01), pages 1034 - 1048, XP008158876, ISSN: 1355-8382, DOI: 10.1261/RNA.5103703 *
WATTS J K ET AL: "Chemically modified siRNA: tools and applications", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 19/20, 1 October 2008 (2008-10-01), pages 842 - 855, XP002558509, ISSN: 1359-6446, [retrieved on 20080707], DOI: 10.1016/J.DRUDIS.2008.05.007 *

Also Published As

Publication number Publication date
KR20190086688A (ko) 2019-07-23
KR102502248B1 (ko) 2023-02-21
CA3042401A1 (fr) 2018-05-11
SG11202104571RA (en) 2021-06-29
MX2019005101A (es) 2019-08-22
JP2022173194A (ja) 2022-11-18
WO2018085198A1 (fr) 2018-05-11
BR112019008810A2 (pt) 2019-07-16
EP3534912A1 (fr) 2019-09-11
KR20210088614A (ko) 2021-07-14
JP7498230B2 (ja) 2024-06-11
AU2017353907A1 (en) 2019-05-23
MX2024000277A (es) 2024-01-31
JP2019533697A (ja) 2019-11-21
CN110290794A (zh) 2019-09-27
JP7130639B2 (ja) 2022-09-05
AU2017353907B2 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
EP3534912A4 (fr) Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer
EP3706803A4 (fr) Conjugués à base d&#39;une biomolécule et leur utilisation
EP3576781A4 (fr) Néoantigènes et leurs utilisations dans le traitement du cancer
EP3507304C0 (fr) Compositions et méthodes pour le traitement du cancer avec des duocars
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3572401A4 (fr) Inhibiteur de ask1, sa méthode de préparation et son utilisation
EP3585389A4 (fr) Traitement du cancer entraîné par egfr avec moins d&#39;effets secondaires
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
EP3541840C0 (fr) Anti-hla-g anticorps et ses utilisation
EP3943093C0 (fr) Utilisation d&#39;akkermansia pasteurisé pour traiter du cancer
EP3366668C0 (fr) Promédicaments de fumarates et leur utilisation pour le traitement de diverses maladies
EP3397261C0 (fr) Particules sub-mitochondriales pour utilisation dans le traitement des maladies cardiovasculaires
EP3619191A4 (fr) Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations
PL3443350T3 (pl) Sposoby monitorowania i leczenia nowotworu
EP3873613A4 (fr) Microarn modifiés par 5-halogéno-uracile et leur utilisation dans le traitement du cancer
EP3453401A4 (fr) Combinaison d&#39;interleukine et utilisation de celle-ci
EP3405499A4 (fr) Traitement du cancer avec des combinaisons d&#39;agents immunorégulateurs
EP3995139C0 (fr) Composition pour utilisation dans le traitement du cancer
EP3272363C0 (fr) Utilisation d&#39;une souche de bactérie génétiquement modifiée, dénommée vnp20009-m, pour la prévention et le traitement des métastases du cancer
EP3538135A4 (fr) Polythérapies de molécules de prednisone et d&#39;uricase et leurs utilisations
EP3484913C0 (fr) Procédés et compositions pour le traitement du cancer
EP3562942A4 (fr) Crispr-arn modifié et ses utilisations
EP3229794C0 (fr) Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque
EP3820492A4 (fr) Apmv et utilisations associées pour le traitement du cancer
EP3570826A4 (fr) Formulations de n-acétylcystéine et leurs utilisations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20200525BHEP

Ipc: A61K 31/7115 20060101ALI20200525BHEP

Ipc: A61K 48/00 20060101ALI20200525BHEP

Ipc: A61P 35/00 20060101ALI20200525BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013929

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031710500

Ipc: C12N0015113000

A4 Supplementary search report drawn up and despatched

Effective date: 20200903

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/7115 20060101ALI20200828BHEP

Ipc: C12N 15/113 20100101AFI20200828BHEP

Ipc: A61P 35/00 20060101ALI20200828BHEP

Ipc: A61K 48/00 20060101ALI20200828BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230528

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260305